1 terminated, 1 unknown, 1 withdrawn. 1 Early Phase 1, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow gancotamab: new trials by email Literature Review of gancotamab trials Research Report on gancotamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets MM-302, Trastuzumab - Brain Metastases, Documented Her2 Overexpression | Early Phase 1 | Withdrawn | Pamela Munster | 2016-04-01 | 2017-05-04 | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients MM-302, Gemcitabine, Capecitabine - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 / Phase 3 | Terminated | Merrimack Pharmaceuticals | 113 | 2014-07-01 | 2017-01-06 |
| Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w - Breast Cancer | Phase 1 | Unknown | Merrimack Pharmaceuticals | 75 | 2011-03-01 | 2017-01-06 |
Breast Neoplasms (2) · Brain Neoplasms (1) · Neoplasm Metastasis (1)
Merrimack Pharmaceuticals (2) · Pamela Munster (1)
United States (2) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Spain (1)